NCT01873950View on ClinicalTrials.gov

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

December 31, 2014

Conditions

Drug-induced Surface ECG Changes

Interventions

DRUG

Ranolazine

DRUG

Dofetilide

DRUG

Verapamil

DRUG

Quinidine sulfate

DRUG

Placebo

All Listed Sponsors

collaborator

Spaulding Clinical Research LLC

OTHER

lead

Food and Drug Administration (FDA)

FED

NCT01873950 - Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects | Biotech Hunter | Biotech Hunter